@article{TLCR33708,
author = {Qiuhua Deng and Yuan Qiu and Junmei Jia and Hailing Tang and Liping Liu and Liyan Huang and Dongyun He and Xiaomeng Dong and Haihong Yang},
title = {Genetic alteration profile of EGFR -mutant resected IIB–IIIA stage NSCLC and correlation to clinical outcomes},
journal = {Translational Lung Cancer Research},
volume = {8},
number = {6},
year = {2019},
keywords = {},
abstract = {Background: Genetic alteration profile of epidermal growth factor receptor (EGFR) mutant resected non- small cell lung cancer (NSCLC) and its relationship with clinical outcomes remains to be illustrated and genetic biomarkers that can predict recurrence need to be figured out.
Methods: Clinicopathological and follow-up information were collected for 99 EGFR-mutant resected NSCLC. Tumor sections were collected for genetic alteration detection. Targeted next-generation sequencing (NGS) was performed to detect somatic mutations within each sample using a 285-gene panel on the Ion Torrent platform.
Results: Concurrent driver gene mutations were detected in 86 participants. Adjuvant therapy was a positive factor in disease-free survival (DFS) period, and patients receiving tyrosine kinase inhibitors (TKIs) gained the longest DFS. A total of 34 concurrent mutant driver genes were found. The median number of mutated driver genes for each sample was 2 (range, 0–12). TP53 and NOTCH1 were the most frequent concurrent mutant driver genes with rates of 53.54% and 25.25% respectively. The number of concurrent mutant genes did not have a significant effect on recurrence. Multivariable analysis found that mutations of ATM (P=0.021), KIT (P=0.002), FGFR2 (P},
issn = {2226-4477}, url = {https://tlcr.amegroups.org/article/view/33708}
}